Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline

Neurobiology of Aging

Volumn 33, Issue 4, 2012, Pages 720-731.e4

  Beydoun, May A ^a   Boueiz, Adel ^b   Abougergi, Marwan S ^b   Kitner Triolo, Melissa H ^a   Beydoun, Hind A ^c   Resnick, Susan M ^a   O'Brien, Richard ^b   Zonderman, Alan B ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Aging; Apolipoprotein E genotype; Cognitive decline; Cognitive impairment; Dementia

Indexed keywords

ADULT; AGED; APOLIPOPROTEIN E EPSILON 4 GENE; ARTICLE; CALIFORNIA VERBAL LEARNING TEST; CAUCASIAN; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; GENE; GENOTYPE; HUMAN; LEARNING; LONGITUDINAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECALL; SEX DIFFERENCE; UNITED STATES; VERBAL FLUENCY TEST; VERBAL MEMORY;

EID: 84856957388     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.05.017     Document Type: Article

References (68)

1. Aggarwal N.T., Wilson R.S., Beck T.L., Bienias J.L., Berry-Kravis E., Bennett D.A. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. Neurocase 2005, 11:3-7.
2. Diagnostic and Statistical Manual of Mental Disorders 1987, American Psychiatric Association, American Psychiatric Association, Washington, DC. third ed., Revised.
3. Benton A.L. Revised Visual Retention Test 1974, The Psychological Corporation, New York. fifth ed.
4. Berr C., Dufouil C., Brousseau T., Richard F., Amouyel P., Marceteau E., Alperovitch A. Early effect of ApoE-epsilon 4 allele on cognitive results in a group of highly performing subjects: the EVA study. Etude sur le Vieillissement Arteriel. Neurosci Lett 1996, 218(1):9-12.
5. Beydoun M.A., Kuczmarski M.T., Mason M.A., Ling S.M., Evans M.K., Zonderman A.B. Role of depressive symptoms in explaining socioeconomic status disparities in dietary quality and central adiposity among US adults: a structural equation modeling approach. Am J Clin Nutr 2009, 90(4):1084-1095.
6. Blair C.K., Folsom A.R., Knopman D.S., Bray M.S., Mosley T.H., Boerwinkle E. APOE genotype and cognitive decline in a middle-aged cohort. Neurology 2005, 64:268-276.
7. Blessed G., Tomlinson B.E., Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry 1968, 114:797-811.
8. Bondi M.W., Salmon D.P., Monsch A.U., Galasko D., Butters N., Klauber M.R., Thal L.J., Saitoh T. Episodic memory changes are associated with the APOE-epsilon four allele in nondemented older adults. Neurology 1995, 45:2203-2206.
9. Brayne C., Harrington C.R., Wischik C.M., Huppert F.A., Chi L.Y., Xuereb J.H., O'Connor D.W., Paykel E.S. Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. Dementia 1996, 7:169-174.
10. Bretsky P., Guralnik J.M., Launer L., Albert M., Seeman T.E. The role of APOE-epsilon4 in longitudinal cognitive decline: Macarthur Studies of Successful Aging. Neurology 2003, 60:1077-1081.
11. Bunce D., Fratiglioni L., Small B.J., Winblad B., Backman L. APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology 2004, 63:816-821.
12. Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J. Cell. Mol. Med 2007, 11:1227-1238.
13. Chey J., Kim J.W., Cho H.Y. Effects of apolipoprotein E phenotypes on the neuropsychological functions of community-dwelling elderly individuals without dementia. Neurosci. Lett 2000, 289:230-234.
14. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Roses A.D., Pericak-Vance M.A., Small G.W., Haines J.L. The apolipoprotein E E4 allele and sex-specific risk of Alzheimer's disease. JAMA 1995, 273:373-374.
15. Cox D.R. Regression models and life tables (with discussion). J. R. Stat. Soc. B 1972, 74:187-220.
16. Delis D.C., Freeland J., Kramer J.H., Kaplan E. Integrating clinical assessment with cognitive neuroscience: construct validation of the California Verbal Learning Test. J. Consult. Clin. Psychol 1988, 56:123-130.
17. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
18. Feskens E.J., Havekes L.M., Kalmijn S., de Knijff P., Launer L.J., Kromhout D. Apolipoprotein e4 allele and cognitive decline in elderly men. BMJ 1994, 309:1202-1206.
19. Fleisher A., Grundman M., Jack C.R., Petersen R.C., Taylor C., Kim H.T., Schiller D.H., Bagwell V., Sencakova D., Weiner M.F., deCarli C., deKosky S.T., van Dyck C.H., Thal L.J. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch. Neurol 2005, 62:953-957.
20. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 1975, 12:189-198.
21. Freedman L.S. Tables of the number of patients required in clinical trials using the logrank test. Stat. Med 1982, 1:121-129.
22. Heckman J.J. Sample selection bias as a specification error. Econometrica 1979, 47:153-161.
23. Henderson A.S., Easteal S., Jorm A.F., Mackinnon A.J., Korten A.E., Christensen H., Croft L., Jacomb P.A. Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 1995, 346:1387-1390.
24. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res 1990, 31:545-548.
25. Hoyt B.D., Massman P.J., Schatschneider C., Cooke N., Doody R.S. Individual growth curve analysis of APOE epsilon four-associated cognitive decline in Alzheimer disease. Arch. Neurol 2005, 62:454-459.
26. Hyman B.T., Gomez-Isla T., Briggs M., Chung H., Nichols S., Kohout F., Wallace R. Apolipoprotein E and cognitive change in an elderly population. Ann. Neurol 1996, 40:55-66.
27. Jonker C., Schmand B., Lindeboom J., Havekes L.M., Launer L.J. Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch. Neurol 1998, 55:1065-1069.
28. Jorm A.F., Mather K.A., Butterworth P., Anstey K.J., Christensen H., Easteal S. APOE genotype and cognitive functioning in a large age-stratified population sample. Neuropsychology 2007, 21:1-8.
29. Juottonen K., Lehtovirta M., Helisalmi S., Riekkinen P.J., Soininen H. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele. J. Neurol. Neurosurg. Psychiatry 1998, 65:322-327.
30. Kawas C., Segal J., Stewart W.F., Corrada M., Thal L.J. A validation study of the Dementia Questionnaire. Arch. Neurol 1994, 51:901-906.
31. Kuller L.H., Shemanski L., Manolio T., Haan M., Fried L., Bryan N., Burke G.L., Tracy R., Bhadelia R. Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke 1998, 29(2):388-398.
32. Kim K.W., Youn J.C., Jhoo J.H., Lee D.Y., Lee K.U., Lee J.H., Woo J.I. Apolipoprotein E epsilon 4 allele is not associated with the cognitive impairment in community-dwelling normal elderly individuals. Int J Geriatr Psychiatry 2002, 17(7):635-640.
33. Lam L.C., Tang N.L., Ma S.L., Lui V.W., Chan A.S., Leung P.Y., Chiu H.F. Apolipoprotein epsilon 4 allele and the two-year progression of cognitive function in Chinese subjects with late-onset Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen 2006, 21:92-99.
34. Lehmann D.J., Refsum H., Nurk E., Warden D.R., Tell G.S., Vollset S.E., Engedal K., Nygaard H.A., Smith A.D. Apolipoprotein E epsilon4 and impaired episodic memory in community-dwelling elderly people: a marked sex difference. The Hordaland Health Study. J. Neurol. Neurosurg. Psychiatry 2006, 77:902-908.
35. Lezak M.D. Neuropsychological Assessment, second ed 1983, Oxford University Press, New York.
36. Lezak M.D. Neuropsychological Assessment 1995, Oxford University Press, New York. third ed.
37. Luczywek E., Nowicka A., Pfeffer A., Czyzewski K., Styczynska M., Lalowski M., Barcikowska M. Cognitive deficits and polymorphism of apolipoprotein E in Alzheimer's disease. Dement. Geriatr. Cogn. Disord 2002, 13:171-177.
38. Martinez M., Campion D., Brice A., Hannequin D., Dubois B., Didierjean O., Michon A., Thomas-Anterion C., Puel M., Frebourg T., Agid Y., Clerget-Darpoux F. Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease. Arch. Neurol 1998, 55:810-816.
39. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
40. Molero A.E., Pino-Ramirez G., Maestre G.E. Modulation by age and gender of risk for Alzheimer's disease and vascular dementia associated with the apolipoprotein E-epsilon4 allele in Latin Americans: findings from the Maracaibo Aging Study. Neurosci. Lett 2001, 307:5-8.
41. Morris J.C. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int. Psychogeriatr 1997, 9(suppl 1):173-176. Discussion, 7-8.
42. Mortensen E.L., Hogh P. A gender difference in the association between APOE genotype and age-related cognitive decline. Neurology 2001, 57:89-95.
43. Nilsson L.G., Adolfsson R., Backman L., Cruts M., Nyberg L., Small B.J., Van Broeckoven C. The influence of APOE status on episodic and semantic memory: data from a population-based study. Neuropsychology 2006, 20:645-657.
44. O'Hara R., Sommer B., Way N., Kraemer H.C., Taylor J., Murphy G. Slower speed-of-processing of cognitive tasks is associated with presence of the apolipoprotein epsilon4 allele. J Psychiatr Res 2008, 42(3):199-204.
45. Packard C.J., Westendorp R.G., Stott D.J., Caslake M.J., Murray H.M., Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., Macfarlane P.W., Jolles J., Perry I.J., Sweeney B.J., Twomey C. Association between apolipoprotein E4 and cognitive decline in elderly adults. J. Am. Geriatr. Soc 2007, 55:1777-1785.
46. Payami H., Grimslid H., Oken B., Camicioli R., Sexton G., Dame A., Howieson D., Kaye J. A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype. Am. J. Hum. Genet 1997, 60:948-956.
47. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med 2004, 256:183-194.
48. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994, 17:525-530.
49. Qiu C., Winblad B., Fratiglioni L. Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population. Neurol. Res 2006, 28:650-656.
50. Reilly S.L., Ferrell R.E., Sing C.F. The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, MN. III. Correlations and covariances. Am. J. Hum. Genet 1994, 55:1001-1018.
51. Reitan R. Trail Making Test: Manual for Administration and Scoring 1992, Reitan Neuropsychological Laboratory, Tucson, AZ.
52. Riley K.P., Snowdon D.A., Saunders A.M., Roses A.D., Mortimer J.A., Nanayakkara N. Cognitive function and apolipoprotein E in very old adults: findings from the Nun Study. J. Gerontol. B Psychol. Sci. Soc. Sci 2000, 55:S69-S75.
53. Romero L.J., Schuyler M., Kamboh M.I., Qualls C., laRue A., Liang H.C., Rhyne R. The APO E4 allele and cognition in New Mexico Hispanic elderly. Ethn. Dis 2002, 12:235-241.
54. Rosen W. Verbal fluency in aging and dementia. J. Clin. Neuropsychol 1980, 2:135-146.
55. Sawyer K., Sachs-Ericsson N., Preacher K.J., Blazer D.G. Racial differences in the influence of the APOE epsilon 4 allele on cognitive decline in a sample of community-dwelling older adults. Gerontology 2009, 55:32-40.
56. Shock N., Greulich R.C., Andres R., Arenberg D., Costa P.T., Lakatta E.G., Tobin J.D. Normal Human Aging: The Baltimore Longitudinal Study of Aging 1984, US Government Printing Office, Washington, DC.
57. Slooter A.J., van Duijn C.M., Bots M.L., Ott A., Breteler M.B., De Voecht J., Wehnert A., de Knijff P., Havekes L.M., Grobbee D.E., Van Broeckhoven C., Hofman A. Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm Suppl 1998, 53:17-29.
58. Small B.J., Graves A.B., McEvoy C.L., Crawford F.C., Mullan M., Mortimer J.A. Is APOE-epsilon4 a risk factor for cognitive impairment in normal aging?. Neurology 2000, 54:2082-2088.
59. Smith G.E., Bohac D.L., Waring S.C., Kokmen E., Tangalos E.G., Ivnik R.J., Petersen R.C. Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology 1998, 50:355-362.
60. Spreen O., Benton A.L. Neurosensory Center Comprehensive Examination for Aphasia: Manual of Directions 1969, University of Victoria, Victoria, BC.
61. Statistics/Data Analysis: Release 10.0 2007, STATA, Stata Corporation, TX, College Station, TX.
62. Swan G.E., Lessov-Schlaggar C.N., Carmelli D., Schellenberg G.D., La Rue A. Apolipoprotein E epsilon4 and change in cognitive functioning in community-dwelling older adults. J. Geriatr. Psychiatry Neurol 2005, 18:196-201.
63. Villasana L., Acevedo S., Poage C., Raber J. Sex- and APOE isoform-dependent effects of radiation on cognitive function. Radiat. Res 2006, 166:883-891.
64. Wilson R.S., Schneider J.A., Barnes L.L., Beckett L.A., Aggarwal N.T., Cochran E.J., Berry-Kravis E., Bach J., Fox J.H., Evans D.A., Bennett D.A. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch. Neurol 2002, 59:1154-1160.
65. Winnock M., Letenneur L., Jacqmin-Gadda H., Dallongeville J., Amouyel P., Dartigues J.F. Longitudinal analysis of the effect of apolipoprotein E epsilon4 and education on cognitive performance in elderly subjects: the PAQUID study. J. Neurol. Neurosurg. Psychiatry 2002, 72:794-797.
66. Yaffe K., Cauley J., Sands L., Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch. Neurol 1997, 54:1110-1114.
67. Yip A.G., Brayne C., Easton D., Rubinsztein D.C. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. J. Med. Genet 2002, 39:639-643.
68. Zonderman A.B., Giambra L.M., Arenberg D., Resnick S.M., Costa P.T., Kawas C.H. Changes in immediate visual memory predict cognitive impairment. Arch. Clin. Neuropsychol 1995, 10:111-123.